SI0809499T1 - Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine - Google Patents

Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Info

Publication number
SI0809499T1
SI0809499T1 SI9630660T SI9630660T SI0809499T1 SI 0809499 T1 SI0809499 T1 SI 0809499T1 SI 9630660 T SI9630660 T SI 9630660T SI 9630660 T SI9630660 T SI 9630660T SI 0809499 T1 SI0809499 T1 SI 0809499T1
Authority
SI
Slovenia
Prior art keywords
cytokine
tri
certain
compounds useful
imidazole compounds
Prior art date
Application number
SI9630660T
Other languages
English (en)
Slovenian (sl)
Inventor
Jerry Leroy Adams
Timothy F. Gallagher
Ravi Shanker Garigipati
Jeffrey Charles Boehm
Joseph Sisko
Zhi-Qiang Peng
John Cheung-Lun Lee
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI0809499T1 publication Critical patent/SI0809499T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
SI9630660T 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine SI0809499T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds
PCT/US1996/000546 WO1996021452A1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
EP96902151A EP0809499B1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Publications (1)

Publication Number Publication Date
SI0809499T1 true SI0809499T1 (en) 2004-04-30

Family

ID=27004764

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630660T SI0809499T1 (en) 1995-01-09 1996-01-11 Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine

Country Status (34)

Country Link
US (5) US5593992A (no)
EP (2) EP0809499B1 (no)
JP (2) JP3330952B2 (no)
CN (1) CN1138546C (no)
AP (1) AP1270A (no)
AR (1) AR002267A1 (no)
AT (1) ATE254613T1 (no)
AU (1) AU705207C (no)
BG (1) BG63769B1 (no)
BR (1) BR9606904A (no)
CA (1) CA2209938A1 (no)
CZ (1) CZ215897A3 (no)
DE (1) DE69630777T2 (no)
DK (1) DK0809499T3 (no)
DZ (1) DZ1961A1 (no)
ES (1) ES2210348T3 (no)
FI (1) FI972901A (no)
HK (1) HK1003623A1 (no)
HU (1) HUP9702409A3 (no)
ID (3) ID23597A (no)
IL (7) IL134322A (no)
IN (3) IN184957B (no)
MA (1) MA23770A1 (no)
MX (1) MX9705142A (no)
NO (3) NO973167L (no)
NZ (1) NZ301204A (no)
OA (1) OA10738A (no)
PL (1) PL322249A1 (no)
PT (1) PT809499E (no)
RU (2) RU2196139C2 (no)
SI (1) SI0809499T1 (no)
SK (1) SK90297A3 (no)
TW (1) TW523511B (no)
WO (1) WO1996021452A1 (no)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
CA2171982C (en) * 1993-09-17 2000-02-01 John Cheung-Lun Lee Drug binding protein
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
BR9607097A (pt) * 1995-01-12 1997-11-11 Smithkline Beecham Corp Novos compostos
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
KR19990077164A (ko) * 1996-01-11 1999-10-25 스티븐 베네티아너 신규 치환된 이미다졸 화합물
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507224A (ja) * 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Ｃｓａｉｄ化合物の血管形成の抑制物質としての使用
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1998007425A1 (en) * 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
HUP9903330A2 (hu) 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
CN1264376A (zh) * 1997-05-22 2000-08-23 G·D·瑟尔公司 作为p38激酶抑制剂的3(5)－杂芳基取代的吡唑化合物
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
PT988301E (pt) 1997-06-12 2006-10-31 Aventis Pharma Ltd Acetais ciclicos de imidazolilo
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
JP2002515915A (ja) * 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999001452A1 (en) * 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (ja) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
AU9449398A (en) * 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
AU1924699A (en) * 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1082320A4 (en) * 1998-05-26 2001-11-21 Smithkline Beecham Corp NEW SUBSTITUTED IMIDAZOLE COMPOUNDS
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CA2341370A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
WO2000040243A1 (en) 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2003502424A (ja) * 1999-06-17 2003-01-21 シオノギ バイオリサーチ コーポレイション Ｉｌ−１２産生の阻害物質
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
EP1235814B1 (en) 1999-11-23 2004-11-03 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
PT1175214E (pt) * 1999-12-08 2005-04-29 Pharmacia Corp Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002005848A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
DE60129330T2 (de) 2000-07-20 2008-04-10 Lauras As Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
EP2404603A1 (en) * 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DE60223339T2 (de) 2001-01-22 2008-08-28 Sankyo Co., Ltd. Durch bicyclische aminogruppen substituierte verbindungen
HUP0303618A3 (en) 2001-03-26 2005-06-28 Ortho Mcneil Pharm Inc Process for the preparation of tetrasubstituted imidazole derivatives and novel cryststalline structures thereof
PE20021017A1 (es) 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1439174B1 (en) * 2001-10-22 2012-03-21 Mitsubishi Tanabe Pharma Corporation 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
ATE448209T1 (de) * 2002-12-16 2009-11-15 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
TW200529845A (en) * 2003-12-12 2005-09-16 Wyeth Corp Quinolines useful in treating cardiovascular disease
RU2006121487A (ru) * 2003-12-18 2007-12-27 Пфайзер Продактс Инк. (Us) СПОСОБЫ ЛЕЧЕНИЯ ОСТРОГО ВОСПАЛЕНИЯ У ЖИВОТНЫХ С ПОМОЩЬЮ ИНГИБИТОРОВ р38 МАР-киназы
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4792396B2 (ja) * 2004-08-31 2011-10-12 三洋化成工業株式会社 界面活性剤
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
MX2007012951A (es) * 2005-03-25 2008-01-11 Glaxo Group Ltd Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona.
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2566772T3 (es) 2006-04-20 2016-04-15 Janssen Pharmaceutica, N.V. Inhibidores de la quinasa c-fms
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
MX2009013176A (es) * 2007-06-05 2011-03-02 Western States Biopharmaceuticals Inc Moleculas superficiales que inducen citosinas de celulas t y metodos de uso.
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CN102573906B (zh) * 2009-02-06 2015-02-11 四川汇宇制药有限公司 抑免蛋白/亲环蛋白和emmprin免疫球蛋白受体超家族成员的双重抑制
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
WO2014028803A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
EP3273955A4 (en) 2015-03-23 2019-05-01 The University of Melbourne TREATMENT OF RESPIRATORY DISEASES
JP2020518621A (ja) * 2017-05-03 2020-06-25 ザ ユニヴァーシティー オブ メルボルン 呼吸器疾患の治療のための化合物
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US20220002269A1 (en) * 2018-11-07 2022-01-06 The University Of Melbourne Novel compounds for the treatment of respiratory diseases
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725399A (en) * 1969-03-11 1973-04-03 Glaxo Lab Ltd METHOD OF PRODUCING 7{62 -ACYLAMIDO-3-METHYLCEPH-3-Em-4-CARBOXYLIC ACID ESTERS
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DD201677A5 (de) * 1980-07-25 1983-08-03 Ciba Geigy Verfahren zur herstellung von trisubstituierten imidazolderivaten
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
AU9137591A (en) * 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
IE914327A1 (en) * 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
EP0624159B1 (en) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
BR9607097A (pt) * 1995-01-12 1997-11-11 Smithkline Beecham Corp Novos compostos

Also Published As

Publication number Publication date
CN1177299A (zh) 1998-03-25
ID23597A (id) 1996-10-10
DK0809499T3 (da) 2004-03-29
NO20016226D0 (no) 2001-12-19
AR002267A1 (es) 1998-03-11
IL134324A (en) 2001-08-26
DE69630777T2 (de) 2004-07-29
IN188338B (no) 2002-09-07
OA10738A (en) 2002-12-11
US5593992A (en) 1997-01-14
RU2196139C2 (ru) 2003-01-10
PT809499E (pt) 2004-04-30
CA2209938A1 (en) 1996-07-18
ID23273A (id) 1996-10-10
EP0809499A1 (en) 1997-12-03
ID23599A (id) 1996-10-10
MX9705142A (es) 1997-10-31
AU705207C (en) 2002-09-19
RU2002122174A (ru) 2004-02-27
NO20016226L (no) 1997-09-08
ES2210348T3 (es) 2004-07-01
WO1996021452A1 (en) 1996-07-18
NO973167L (no) 1997-09-08
AP1270A (en) 2004-04-16
HUP9702409A2 (hu) 1999-05-28
US5663334A (en) 1997-09-02
IN188339B (no) 2002-09-07
JP3330952B2 (ja) 2002-10-07
NO973167D0 (no) 1997-07-08
PL322249A1 (en) 1998-01-19
BG101727A (en) 1998-03-31
EP0809499B1 (en) 2003-11-19
FI972901A0 (fi) 1997-07-08
AU4657296A (en) 1996-07-31
CZ215897A3 (cs) 1998-04-15
IL134323A (en) 2001-11-25
IL134324A0 (en) 2001-04-30
EP0809499A4 (en) 1998-10-14
HUP9702409A3 (en) 1999-06-28
IL134322A (en) 2001-09-13
AU705207B2 (en) 1999-05-20
IN184957B (no) 2000-10-07
NO20016225D0 (no) 2001-12-19
JPH10512555A (ja) 1998-12-02
HK1003623A1 (en) 1999-02-12
US20020188122A1 (en) 2002-12-12
BR9606904A (pt) 1997-10-21
US6222036B1 (en) 2001-04-24
EP1264827A1 (en) 2002-12-11
DZ1961A1 (fr) 2002-02-17
IL116455A0 (en) 1996-03-31
ATE254613T1 (de) 2003-12-15
NZ301204A (en) 1999-05-28
SK90297A3 (en) 1998-01-14
TW523511B (en) 2003-03-11
IL134322A0 (en) 2001-04-30
BG63769B1 (bg) 2002-12-29
AP9701021A0 (en) 1997-07-31
DE69630777D1 (de) 2003-12-24
IL116455A (en) 2001-07-24
MA23770A1 (fr) 1996-10-01
IL134323A0 (en) 2001-04-30
US6103936A (en) 2000-08-15
FI972901A (fi) 1997-09-08
NO20016225L (no) 1997-09-08
JP2002105047A (ja) 2002-04-10
CN1138546C (zh) 2004-02-18

Similar Documents

Publication Publication Date Title
SI0809499T1 (en) Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
IL143517A (en) Imidazole compounds
ZA9610858B (en) Heteroclyclic compounds.
IL125282A0 (en) Novel substituted imidazole compounds
AU1642095A (en) 3,5-disubstituted tetrahydrofuran-2-ones
GR3033254T3 (en) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
ZA965505B (en) Novel compounds.
AU1416195A (en) Substituted 1,2,3,4-tetrahydro-5-nitro pyrimidines
ZA961522B (en) Fungicidal composition
GB9503061D0 (en) Polymeric compounds
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
GB9622283D0 (en) 3,4,5-Trifluorophenyl 4- cyclohexylbenzoates
ZA962753B (en) 1,3-Dihydro-2H-imidazol-2-one derivatives.
ZA964560B (en) Anit-viral compounds.
AU2145892A (en) 2-methyl-5-hydroxymethyl- and 2,5-dimethyl-3,4-dihydroxypyrrolidines
ZA965465B (en) 2,4,5-Trisubstituted phenylketoenois
AUPP003297A0 (en) 4,5-diaryloxazole compounds
AU7295796A (en) 1,3,5-oxadiazines as molluscicides
AU2137095A (en) Heterocyclyl-1,3,4-thiadiazolyloxyacetamides
GB2293996B (en) System for working wood
ZA961046B (en) Fungicidal composition.
ZA965332B (en) Melosis regulating compounds
AU696576B2 (en) 4-amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds
AU4256896A (en) Fungicidal 1,3,4-oxathiazol-2-ones
GB9510132D0 (en) u, m, p, r, 60